Direct oral anticoagulants were introduced in the market to simplify the anticoagulation treatment and eventually, replace warfarin. DOACs offer pharmacological advantages over VKAs; they have predictable dose responses thereby eliminating the need for routine monitoring, fewer dietary restrictions, limited drug-drug interactions and rapid onset/offset of action. Large randomized clinical trials for all four DOACs in AF have shown these drugs to be safe and efficacious for stroke prevention in AF patients and possibly better than warfarin. The incidence of major bleeding events with DOACs were found to be similar to or lower than with warfarin. However, in the absence of an no head-to-head comparative trials with DOACs, one cannot be considered superior over the others. In this part two of the four-part whitepaper, we provide an overview of the current in-market DOACs along with their clinical profiles, trials in AF, marketing and promotional data, ongoing clinical trials and real-world evidence generated for each DOAC.